This website uses cookies

Read our Privacy policy and Terms of use for more information.

Good afternoon,

Weil’s wind-down keeps minting rivals’ platforms. Gibson Dunn confirmed it is taking more than 120 Weil Gotshal & Manges funds lawyers, including 23 partners and co-managing partner Jonathon Soler, across New York, Washington and London — one of the largest funds benches in Big Law. Simpson Thacher became the third major US firm in a month to stop publishing its finances, and tracked lateral moves have already passed 1,571 this year.

On the client side, Nvidia pushed out Jensen Huang and named CFO Colette Kress interim chief, throwing the board’s crisis, securities and national-security work into overdrive as Huang retained Paul Weiss and the Senate called him to testify. Dealmakers are weighing a possible SpaceX–Tesla tie-up and a surge of China pharma licensing, all against a 10-year Treasury back above 5%.

Now, on to what matters for your practice today.

Today’s Talking Points

-Gibson Dunn lands 120 Weil funds lawyers and co-managing partner Jonathon Soler; Dechert and Debevoise add in London

-Simpson Thacher stops publishing financials; Cahill confirms it has fielded merger approaches

-Nvidia ousts Jensen Huang, names Colette Kress interim CEO; Huang hires Paul Weiss as the Senate calls him to testify

-Companies start selling litigation liabilities to investors as mass-tort and defense costs climb

-SpaceX–Tesla merger talks advance; CD&R and GTCR walk away from $24B Global Payments

-China pharma licensing nears $200B a year as the US and China weigh biotech investment curbs

-Fed sets just seven 2027 meetings; the 10-year tops 5%; the US confirms $500M of yen intervention

-US home sales fall to their lowest since 2010

Talent Strategy

Latest Moves

  • Gibson Dunn is taking more than 120 funds lawyers from Weil Gotshal & Manges, including 23 partners, across New York, Washington and London — among them Weil co-managing partner and private funds co-head Jonathon Soler. The lift follows funds co-leader Ramona Nee’s earlier move to Kirkland & Ellis.

  • Sidley Austin is set to add at least 50 Weil lawyers, including 12 partners, in New York.

  • Dechert is close to hiring Malcolm Lombers, a former Herbert Smith Freehills Kramer leadership contender and Legal 500 Hall of Fame partnership lawyer, into its London corporate practice, with a first-quarter 2027 start.

  • Debevoise & Plimpton hired a London funds partner from White & Case, its second secondaries hire in two months, while Hogan Lovells Cadwalader took a debt capital markets partner from HSF Kramer.

  • Crowell & Moring added Ryan Nowicki as senior tax counsel in Los Angeles.

What today’s moves tell us: Weil’s dissolution is still the single biggest supplier of partners to its rivals, and firms are paying up for portable funds, secondaries and corporate talent on both sides of the Atlantic.

Check our Rolodex newsletter delivered on Monday at 7:30 am for a weekly overview of the lateral market and executive moves.

Operations and Strategy

Firms are tightening what they disclose even as the lateral market runs hot.

Simpson Thacher & Bartlett will stop publicly releasing its financial results, the third major US firm in just over a month to do so. For a firm long near the top of the profitability tables, going dark removes a benchmark rivals and recruiters have leaned on, and it signals that elite firms increasingly treat published economics as a competitive liability rather than a badge.

Cahill Reindel & Gordon confirmed it has fielded approaches from other firms about a combination, with its chair insisting the firm “remains incredibly financially strong.” The disclosure is a reminder that even healthy mid-size firms are now being courted as scale becomes the price of staying competitive.

Gibson Dunn’s 120-lawyer Weil lift is as much an operations story as a talent one. Absorbing 23 partners and a transatlantic funds practice in a single move tests integration, conflicts clearance and compensation systems at once, and it hands Gibson Dunn one of the deepest funds benches in the market almost overnight.

Practices

Corporate Governance and Investigations

A founder-level blowup at the world’s most valuable chip maker is the kind of mandate that routes straight to a short list of crisis, securities and national-security specialists. For general counsel and boards, Nvidia is a live case study in how fast a personal scandal becomes a disclosure, congressional-testimony and foreign-influence problem all at once.

Selected Press:

  • Nvidia ousted founder-CEO Jensen Huang and named CFO Colette Kress interim chief; Huang has retained Paul Weiss.

  • The Senate Banking Committee chair called Huang and Commerce Secretary Howard Lutnick to testify, and President Trump floated Tim Cook as a successor.

  • Wachtell Lipton, with former federal prosecutor Joon Kim, is still running the board’s review of Huang’s ties to Alice Huang; Deputy Attorney General Todd Blanche said the DOJ has not concluded she was a Chinese spy.

  • Scrutiny grew over Nvidia’s decision to stop disclosing Singapore revenue, once 22% of sales.

M&A, Private Equity and Capital Markets

Dealmakers are testing how far they can push on size and structure. A possible SpaceX–Tesla combination and a run of bank and pharma deals point to busy sell-side, financing and antitrust pipelines, while two sponsors walking away from Global Payments shows buyers still have price discipline.

Selected Press:

  • SpaceX and Tesla are advancing merger talks, with an announcement possible as soon as December.

  • CD&R and GTCR dropped their pursuit of $24 billion payments processor Global Payments.

  • Hancock Whitney agreed to buy Trustmark in a $3.2 billion all-stock deal at a 20% premium.

  • Pfizer raised up to $1.5 billion from Blackstone Life Sciences for its obesity-drug push, and EasyJet holders approved Apollo’s £5.7 billion buyout, which still faces an EU ownership review.

  • BC Partners is buying an Investcorp business-development company as the $1.8 trillion private-credit market consolidates.

Cross-Border M&A and National Security

Global drugmakers are licensing Chinese innovation at a scale that is starting to collide with national-security policy, the kind of split-screen that keeps regulatory, CFIUS and export-control teams in every major deal. Trade policy has become as central to these transactions as price, with boards now asking as much about investment limits and export controls as they do about synergies.

Selected Press:

  • Licensing of Chinese biotech by AstraZeneca, Bristol-Myers Squibb, Roche, Pfizer and Eli Lilly has pushed headline deal value toward $200 billion a year, per Bank of America.

  • The US and China are both proposing tighter biotech foreign-investment limits and export controls, Arnold & Porter partners note.

  • Eli Lilly won the first Chinese approval for a GLP-1 weight-loss pill, orforglipron.

Litigation and White-Collar

A new market for selling legal risk is forming even as enforcement and privacy exposure climbs. For litigators and their clients, liability divestitures, insider-trading enforcement and a fresh wave of AI suits all point to steady contested work.

Selected Press:

  • Companies are selling existing and future litigation liabilities to investors such as Global Risk Capital, Acorn Investment Partners and Third Point-backed Delticus through “liability divestitures.”

  • A longtime Cravath, Swaine & Moore employee was arrested for allegedly trading on client merger information for more than $70,000.

  • Nonprofits sued OpenAI, Anthropic, SpaceX, Meta and Google to halt frontier-AI development, and Meta’s Facebook heads to a July trial in the DC attorney general’s Cambridge Analytica case.

Where the Work Sits

***

The Nvidia crisis is close to full employment for a narrow set of practices: securities-defense teams facing a class action and possible SEC review, white-collar and national-security lawyers mapping the Alice Huang and Megaspeed questions, and governance counsel steering an interim-CEO transition and congressional testimony. High-end matters like these rarely go to the low bidder.

Cross-border licensing into China is generating CFIUS, export-control and deal-structuring mandates as Washington and Beijing both tighten biotech rules, and the push to place deals around those limits will keep regulatory and transactional teams busy well before any corporate M&A arrives. In credit, BC Partners’ purchase of an Investcorp vehicle is the latest sign that private-credit stress is turning into consolidation and liability-management, creditor-rights and fund-restructuring work as the $1.8 trillion market sorts winners from losers.

The new business of selling litigation liabilities creates its own advisory layer — structuring the vehicles, pricing reserves and defending the claims once they change hands — a reminder that even risk transfer generates sophisticated, billable matters for the firms that can execute it.

Global Markets

Rates and intervention are back at the center of the client playbook. Executives and fund managers are recalibrating to a Fed that will meet only seven times in 2027 and a 10-year Treasury back above 5%, and with a 50bp December hike again in play, decision-makers are weighing whether to lock financing now. The message many advisers are giving clients is that the cost of money has reset higher and is not obviously coming down, so waiting for cheaper financing looks less like patience and more like a bet.

Selected Press:

  • The Fed will hold just seven meetings in 2027, and US yields hit a one-month high as 50bp-hike odds rose.

  • The US confirmed about $500 million of yen intervention, and gold fell to a one-year low.

  • US home sales dropped to their lowest since 2010, while UK output grew 0.7% in the third quarter.

  • Trump said the US no longer needs an Iran deal, and India moved to bar private equity firms from controlling multiple non-bank lenders.

Stories to Watch

  • US PPI (today) — the week’s last inflation read, and a direct input into the December rate debate.

  • Nvidia Q3 earnings (Tuesday) and CEO search — the first results since Huang’s exit, and a test of how much the franchise depends on him.

  • Anthropic’s IPO debut (around Nov. 19) — the listing many investors treat as the linchpin of the AI trade.

  • Home Depot and Target earnings (next week) — reads on the consumer as housing activity sits at a 2010 low.

  • US Senate energy-permitting bill — votes expected next week, with limits on judicial review drawing opposition.

  • Democratic oversight agenda (January) — subpoena fights and executive-power clashes general counsel are already preparing for.

That’s the rundown. See you next where law meets the markets.

-The BigLaw Markets Team

*DISCLAIMER: BigLaw Markets analyzes publicly available information, filings, press releases, and news stories published by reputable media sources to deliver content that highlights demand for legal services. Certain production processes may be supported by proprietary AI tools and are subject to human editorial judgement and review.

Thanks for reading!

We’d like your feedback. Please email thoughts and suggestions to [email protected].